Global Transcatheter Embolization And Occlusion Devices Market, By Type (Coil and Non-Coil), By Application (Peripheral Vascular Disease, Oncology, Neurology, and Urology), By End User (Hospitals, Ambulatory Surgical Centers, and Clinics), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 99768
- Number of Pages: 360
In 2022, the Global Transcatheter Embolization and Occlusion Devices Market was valued at USD 4.4 Billion and expected to grow USD 11 Billion in 2032. Between 2023 and 2032, this market is estimated to register a CAGR of 9.8%.
Transcatheter embolization and occlusion devices allow for the insertion or passage of a synthetic embolus into the body through a specific body part while using a catheter. As part of interventional radiology, transcatheter embolization is a minimally invasive technique used to stop blood flow to malignancies. To identify many strategies to target tumors, synthetic materials are occasionally employed to coat chemotherapeutic medications to carry out simultaneous acts of blood supply blocking and causing cytotoxicity.
The procedures also aid in removing anomalous connections between the veins and arteries and in preventing or controlling aberrant bleeding. The treatment of aneurysms is also aided by it. In addition, unlike open and invasive surgical techniques, transcatheter embolization is particularly effective at controlling bleeding without being invasive.
*Actual Numbers Might Vary In The Final Report
- Transcatheter Embolization and Occlusion Procedures Are Minimally Invasive: Transcatheter embolization and occlusion procedures can provide minimally invasive solutions by inserting catheters through blood vessels for embolization/occlusion purposes, thus eliminating open surgery procedures while shortening recovery times.
- Clinical Applications: These devices can be utilized in various clinical applications, including embolization of vessels and aneurysm treatment; embolization of uterine fibroids for embolization purposes and arteriovenous malformation management.
- Embolization Materials: Devices typically employ embolic materials to block or reduce blood flow. Common embolic agents include coils, particles, glue and foam.
- Vascular Applications: Transcatheter embolization and occlusion techniques can be utilized in treating various vascular ailments including arterial aneurysms, vein malformations and varicoceles.
- Oncology Applications: These devices can also be utilized in oncology to directly embolize tumor blood vessels or block their access, and therefore target tumors more effectively.
- Gynecological Applications: Uterine Fibroid Embolization is a common procedure utilized in order to address symptoms caused by uterine fibroids.
The Usage of These Devices As a Less Painful Alternative to Open Surgery Drives the Market
A synthetic embolus is positioned or inserted into the blood vessel using a tiny catheter during transcatheter embolization and occlusion (TEO), a minimally invasive (MI) procedure used to stop blood flow to the tumor or other parts of the body. The global burden of chronic diseases has led to a large growth in the transcatheter embolization and occlusion devices market. In order to identify many strategies to target tumors, synthetic compounds are occasionally employed to coat chemotherapeutic medications, performing simultaneous activities of blood supply blocking and producing cytotoxicity.
The procedures also aid in removing improper connections between the veins and arteries and in preventing or controlling abnormal bleeding. Moreover, it aids in the management of aneurysms. Also, there has been a rise in the usage of these devices as a less painful alternative to open surgery with smaller incisions. The Global Transcatheter Embolization and Occlusion Devices Market are projected to grow as a result of these technological developments in the industry.
High Cost And Lack of Skilled Professionals Are the Reason for Restraint
The transcatheter embolization and occlusion devices market has been growing steadily in recent years, driven by the increasing adoption of minimally invasive techniques and the rising incidence of various medical conditions that require these devices. However, there are also several factors such as High cost, Lack of skilled professionals, Regulatory hurdles, Competition from alternative treatments, and Adverse events that could act as restraints on the growth of the market.
However, ongoing innovation and improvements in device technologies, along with efforts to increase access to skilled professionals and reduce costs, are likely to continue driving growth in the market in the coming years.
AI And Robotics Are Being Used More In Healthcare, Even During Minimally Invasive Treatments
In the upcoming years, the market for transcatheter embolization and occlusion devices is anticipated to present a number of opportunities due to the rising demand for minimally invasive procedures and ongoing advancements in device technology. Devices for transcatheter embolization and occlusion are being created and investigated for new indications and uses, including the treatment of uterine fibroids and prostate cancer.
These new applications can widen the market and give device makers more chances to present cutting-edge fixes. AI and robotics are being used more and more in healthcare, even during minimally invasive treatments. Robotics and AI could be used in conjunction with transcatheter embolization and occlusion devices to enhance accuracy and results while opening up new business prospects for device producers.
Overall, due to continued innovation and rising demand for minimally invasive procedures, the transcatheter embolization and occlusion devices market is anticipated to present a number of opportunities in the years to come. Device makers who can create cutting-edge, secure, and efficient products will be well-positioned to seize these opportunities and increase their market share.
Rising Demand for Minimally Invasive Procedures is the main reason For the usage of these devices
The transcatheter embolization and occlusion devices market is undergoing several key trends that are shaping the market landscape. Transcatheter embolization and occlusion procedures are minimally invasive, which means they offer several advantages over traditional surgical techniques. Patients generally experience less pain, shorter hospital stays, and quicker recovery times. This has led to increasing adoption of these procedures, particularly in developed countries. Cardiovascular and oncology conditions are some of the leading causes of death worldwide.
As the global population continues to age and lifestyles continue to change, the prevalence of these conditions is expected to increase. This is driving demand for transcatheter embolization and occlusion devices, which are used to treat a range of conditions in these areas.
Non-Coil Segment of Type Are Expected to be the Dominator in the Market
Based on type, the market for transcatheter embolization and occlusion devices is segmented into coil and non-coil. Among these types, the non-coil segment is the most lucrative in the global transcatheter embolization and occlusion devices market. The usage of these devices has been credited with the quick expansion of this product category since it helps prevent issues including inaccurate deployment, catheter entrapment, and balloon deflation brought on by coiling.
In order to take benefit of the advantages associated with non-coil devices, surgeons are turning more and more toward them. Hence, the market for transcatheter embolization and occlusion devices benefits from the rising demand for illness treatment.
Neurology Segment is Expected to be the Dominator in the Market
By Application, the market is further divided into peripheral vascular disease, oncology, neurology, urology, and others. The neurology segment is estimated to be the most lucrative segment in the global transcatheter embolization and occlusion devices market, with a market value of US$ 1.54 Bn and a projected CAGR of 7.5%, in 2022.
Also, the oncology segment is estimated to account for US$ 1.2 Bn and a revenue share of 27.4%. Within the oncology field, transcatheter embolization and occlusion devices are primarily used to treat liver cancer, as well as tumors in the kidney, lung, and other parts of the body. These devices are designed to block or reduce blood flow to the tumor, which can shrink the tumor or prevent it from growing further.
Hospitals are expected to be the Dominator in the Market
Based on end-user, the market is segmented into hospitals, ambulatory surgical centers, clinics, and others. Among these end-users, the hospital segment is estimated to be the most lucrative segment in the global transcatheter embolization and occlusion devices market, with the largest revenue share of 30.5% and a projected CAGR of 8.5% during the forecast period. The primary reason for hospitals’ dominance in the market is their ability to provide comprehensive medical services, including diagnostics, treatment, and post-treatment care.
Hospitals typically have a wide range of medical specialties and advanced imaging technologies, which are essential for the diagnosis and treatment of complex medical conditions that require transcatheter embolization and occlusion devices. Additionally, hospitals often have the resources and expertise required to handle emergency cases, which can also require the use of these devices. Ambulatory surgery centers (ASCs) and specialty clinics are also important to end users in the market, particularly for procedures that can be performed on an outpatient basis. ASCs and specialty clinics can provide a more convenient and cost-effective alternative to hospital-based care, particularly for patients with less complex conditions.
Key Market Segments
Based on Type
- Pushable Coils
- Detachable Coils
- Flow Diverting Devices
- Embolization Particles
- Liquid Embolics
Based on Application
- Peripheral Vascular Disease
- Other Applications
Based on End-User
- Ambulatory Surgical Centers
- Other End-User
North America is expected to be the dominant region in the market
North America is estimated to be the most lucrative market in the global transcatheter embolization and occlusion devices market, with the largest market share of 40%, and is expected to register a CAGR of 7.8% during the forecast period. The market is driven by the growing prevalence of chronic diseases such as cancer, heart diseases, and neurological disorders, as well as the increasing adoption of minimally invasive procedures. The presence of well-established healthcare infrastructure and high healthcare expenditure also contribute to market growth.
However, Europe is the second-largest market for transcatheter embolization and occlusion devices, with Germany, France, and the United Kingdom being the largest contributors to the market. The region is driven by the increasing incidence of chronic diseases, the growing aging population, and the presence of advanced healthcare facilities. Overall, the transcatheter embolization and occlusion devices market is driven by a combination of demographic, epidemiological, and healthcare-related factors. The market dynamics vary by region, with some regions experiencing faster growth than others.
- North America
- The US
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- The Czech Republic
- Rest of Eastern Europe
- South Korea
- Australia & New Zealand
- Rest of APAC
- Latin America
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Rest of MEA
Key Players Analysis
The transcatheter embolization and occlusion devices market is highly competitive, the major players in the market account for a significant share of the global market. In 2021, Boston Scientific Corporation, Medtronic, and Stryker Corporation were identified as the leading players in the transcatheter embolization and occlusion devices market, together accounting for a significant share of the market.
These key players are focusing on product innovation and new product launches to maintain their market position. For instance, in 2021, Boston Scientific Corporation launched its new Embolization Particle, Embozene TANDEM Microspheres, for the treatment of hypervascular tumors. Similarly, in 2020, Stryker Corporation launched the CrossBoss Coronary CTO Crossing Catheter, an advanced atherectomy device used for the treatment of chronic total occlusions.
Overall, the market for transcatheter embolization and occlusion devices is expected to remain competitive and continue to grow as new and innovative products are introduced to the market.
Listed below are some of the most prominent transcatheter embolization and occlusion devices industry players.
Market Key Players
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic, Inc.
- DePuy Synthes
- Stryker Corporation
- Cordis Corporation
- Jude Medical
- Pfizer, Inc.
- Sirtex Medical
- Other Key Players
- The PipelineTM Flex Embolization Device with Shield TechnologyTM was approved by the US Food and Drug Administration (FDA) in April 2021, according to a statement from Medtronic plc. By introducing the first surface-modified implant device that demonstrates the reduction in material thrombogenicity, or a reduction in the tendency of the surface treatment material to create clots, Medtronic introduced the first surface-modified implant device using Shield Technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy.
- TheraSphere Y-90 Glass Microspheres, an interventional radiology therapy created by Boston Scientific for the transcatheter treatment of patients with hepatocellular carcinoma, received FDA approval in March 2021. (HCC).
Report Features Description Market Value (2022) USD 4.4 Billion Forecast Revenue (2032) USD 11 Billion CAGR (2023-2032) 9.8% Base Year for Estimation 2022 Historic Period 2016-2021 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Type(Coil and Non Coil), By Application(Perishable Vascular Diesease, Neurology, Oncology, Urology, and Other Applications), By End-User(Hospitals, Ambulatory Surgical Centers, Clinics, and Other End-User) Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; the Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Boston Scientific Corporation, Terumo Corporation, Medtronic, Inc., DePuy Synthes, Stryker Corporation, Cordis Corporation, St. Jude Medical, Pfizer, Inc., Sirtex Medical, Nordian. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)What are transcatheter embolization and occlusion devices?
These are medical devices used in minimally invasive procedures to block or reduce blood flow to specific areas within the body, often by inserting catheters through blood vessels.How big is the Transcatheter Embolization And Occlusion Devices Market?
The global Transcatheter Embolization And Occlusion Devices Market size was estimated at USD 4.4 Billion in 2022 and is expected to reach USD 11 Billion in 2032.What is the Transcatheter Embolization And Occlusion Devices Market growth?
The global Transcatheter Embolization And Occlusion Devices Market is expected to grow at a compound annual growth rate of 9.8%. From 2023 To 2032Who are the key companies/players in the Transcatheter Embolization And Occlusion Devices Market?
Some of the key players in the Transcatheter Embolization And Occlusion Devices Markets are Boston Scientific Corporation, Terumo Corporation, Medtronic, Inc., DePuy Synthes, Stryker Corporation, Cordis Corporation, Jude Medical, Pfizer, Inc., Sirtex Medical, Nordian, Other Key PlayersWhat clinical applications do these devices have?
They are used in a variety of applications, including vascular embolization, aneurysm treatment, uterine fibroid embolization, and arteriovenous malformation management.What materials are used for embolization in these devices?
Common embolic agents include coils, particles, glue, and foam, which are used to block or reduce blood flow.In which medical specialties are transcatheter embolization and occlusion devices used?
They are used in vascular applications, oncology, gynecology (e.g., uterine fibroid embolization), and neurology (e.g., treating cerebral aneurysms and arteriovenous malformations).What are the benefits of these minimally invasive procedures?
They offer reduced invasiveness, shorter recovery times, and less post-operative pain compared to traditional open surgery.
| Single User
USD / per unit
| Multi User
USD / per unit
| Corporate User
USD / per unit
|Report Library Access
|Data Set (Excel)
|Company Profile Library Access
|up to 10 hrs work
|up to 30 hrs work
|up to 20 hrs
|up to 40 hrs
|up to 50 hrs
|Up to 20% off on next purchase
|Up to 25% off on next purchase
|Up to 30% off on next purchase
|Buy Now ($ 3,499)
|Buy Now ($ 4,299)
|Buy Now ($ 4,999)